---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-037770"
form_type: "8-K"
ticker: "AIDX"
cik: "0001139685"
company_name: "20/20 Biolabs, Inc."
filed_at: "2026-04-01T23:59:59+00:00"
generated_at: "2026-05-15T07:56:37.429076+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# 20/20 BioLabs FY 2025 revenue $2.0M (+17%); gross margin expands; $5M private placement

## Summary
- Revenue $2.0M (+17% YoY); gross profit $0.6M (+68%); gross margin 29.6% vs 20.6%.
- Operating expenses down 35% to $3.9M; net loss improved 33% to ($3.7)M; cash $1.0M.
- Completed $5.0M private placement Feb 2026; up to $40M available in tranches.
- MDH awarded $520K to 18 fire departments for OneTest MCED; Medicare MCED pathway law signed Feb 2026.
- Launched OneTest for Longevity with IBM AI; exclusive license with ROKIT Healthcare for CKD prediction.

## SEC filing metadata
- accession: 0001213900-26-037770
- form_type: 8-K
- ticker: AIDX
- cik: 0001139685
- company_name: 20/20 Biolabs, Inc.
- filed_at: 2026-04-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1139685/000121390026037770/0001213900-26-037770-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1139685/000121390026037770/ea028443201-8k_2020bio.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-037770
- JSON: https://secwatch.observer/filing/0001213900-26-037770.json
- Plain text: https://secwatch.observer/filing/0001213900-26-037770.txt

## Key facts
- Earnings Releases
  20/20 Biolabs, Inc. reported the full year ended December 31, 2025 results: revenue $2.0 million, net income ($3.7) million.
  - Period: the full year ended December 31, 2025
  - Revenue: $2.0 million
  - Net income: ($3.7) million
  - Result: reported results
  source text: Revenue of $2.0 million for FY 2025, representing an increase of 17% over FY 2024. ● Deferred revenue totaled approximately $0.4 million as of December 31, 2025. ● Gross profit of $0.6 million for FY 2025, representing an increase of 68% over FY 2024. Gross margin was 29.6% in FY 2025, compared to 20.6% in FY 2024. ● Total operating expenses decreased 35% to $3.9 million in FY 2025 compared to $6.0 million in FY 2024. ● FY 2025 net loss improved 33% to ($3.7) million, compared to ($5.6) million in FY 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1139685/000121390026037770/0001213900-26-037770-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.